Claims
- 1. An isolated or purified polypeptide comprising:
(a) the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 34, or 46; or (b) an amino acid sequence encoded by a polynucleotide which will hybridize under highly stringent conditions with a probe having the complement of the coding sequence shown in SEQ ID NO: 1, 3, 5, 7, 33, or 45; wherein said polypeptide has osteoregulin activity.
- 2. An isolated or purified polypeptide comprising an amino acid sequence having at least 90% identity to an amino acid sequence comprising SEQ ID NO: 2, 4, 6, 8, 34, or 46, wherein said polypeptide has osteoregulin activity.
- 3. A heterologous polypeptide comprising:
(a) the amino acid sequence of SEQ ID NO: 2, 4, 6, 8, 34, or 46; or (b) an amino acid sequence encoded by a polynucleotide which will hybridize under highly stringent conditions with a probe having the complement of the coding sequence shown in SEQ ID NO: 1, 3, 5, 7, 33, or 45; wherein said polypeptide has osteoregulin activity, and wherein said polypeptide is produced by expression of a heterologous polynucleotide in a host.
- 4. A heterologous polypeptide comprising an amino acid sequence having at least 90% identity to an amino acid sequence comprising SEQ ID NO: 2, 4, 6, 8, 34, or 46, wherein said polypeptide has osteoregulin activity, and wherein said polypeptide is produced by expression of a heterologous polynucleotide in a host.
- 5. An isolated or purified polynucleotide comprising:
(a) a nucleic acid sequence encoding a polypeptide according to claim 1;(b) the coding sequence shown in SEQ ID NO: 1, 3, 5, 7, 33, or 45; or (c) a nucleic acid sequence which hybridizes to a probe having the complement of a sequence according to (a) or (b) under highly stringent conditions.
- 6. An isolated or purified polynucleotide comprising:
(a) a nucleic acid sequence encoding a polypeptide according to claim 2; or (b) a nucleic acid sequence which hybridizes to a probe having the complement of a sequence according to (a) under highly stringent conditions.
- 7. An antibody that selectively binds to a polypeptide according to claim 1 or 3.
- 8. An antibody that selectively binds to a polypeptide according to claim 2 or 4.
- 9. A vector comprising a polynucleotide according to claim 5.
- 10. A vector comprising a polynucleotide according to claim 6.
- 11. A host expressing a heterologous protein according to claim 3.
- 12. A host expressing a heterologous protein according to claim 4.
- 13. A genetically-modified, non-human mammal, wherein the modification results in a functionally disrupted osteoregulin gene.
- 14. The mammal of claim 13, wherein said mammal is heterozygous for said modification.
- 15. The mammal of claim 13, wherein said mammal is homozygous for said modification.
- 16. The mammal of claim 13, wherein said mammal is a rodent.
- 17. The rodent of claim 16, wherein said rodent is a mouse.
- 18. A genetically-modified animal cell, wherein the modification comprises a functionally disrupted osteoregulin gene.
- 19. The animal cell of claim 18, wherein said cell is heterozygous for said modification.
- 20. The animal cell of claim 18, wherein said cell is homozygous for said modification.
- 21. The animal cell of claim 18, wherein said cell is an embryonic stem (ES) cell or an ES-like cell.
- 22. The animal cell of claim 18, wherein said cell is human.
- 23. The animal cell of claim 18, wherein said cell is murine.
- 24. A method of screening for an agent that modulates an osteoregulin activity, said method comprising contacting an agent with an osteoregulin polypeptide and measuring the activity of said osteoregulin, wherein a difference between said osteoregulin activity in the presence of the agent and in the absence of the agent is indicative that the agent modulates said activity.
- 25. A method of screening for an agent that modulates an osteoregulin activity by modulating osteoregulin expression, said method comprising contacting an agent with a cell containing a nucleotide sequence comprising an osteoregulin gene regulatory element operably linked to a coding sequence, and measuring the expression of said coding sequence, wherein a difference between said expression in the presence of the agent and in the absence of the agent is indicative that the agent modulates osteoregulin expression.
- 26. A method of treating a mammal to regulate bone mass and/or density, adiposity, vascular flexibility, and/or atherosclerotic plaque calcification, said method comprising administering an osteoregulin modulator to said mammal.
- 27. The method of claim 26, wherein said modulator is an osteoregulin antagonist and wherein said antagonist is administered to increase bone mass and/or bone density.
- 28. The method of claim 26, wherein said modulator is an osteoregulin agonist and wherein said agonist is administered to reduce adiposity.
- 29. The method of claim 26, wherein said modulator is an osteoregulin antagonist and wherein said antagonist is administered to increase atherosclerotic plaque stability.
- 30. The method of claim 26, wherein said modulator is an osteoregulin agonist and wherein said agonist is administered to increase vascular flexibility.
- 31. A method for producing a polypeptide of claim 3 or 4, said method comprising:
(a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell comprises a heterologous polynucleotide that encodes said polypeptide and said polynucleotide is operably linked to a promoter sequence; and (b) recovering said polypeptide.
- 32. The method of claim 31, wherein said polynucleotide comprises SEQ ID NO: 1, 3, 5, or 7.
- 33. The method of claim 31, wherein said cell is a bacterial cell, and said polynucleotide comprises SEQ ID NO: 33 or SEQ ID NO: 45.
Parent Case Info
[0001] This application claims priority, under 35 U.S.C. §119(e), from U.S. provisional application No. 60/185,617, filed Feb. 29, 2000, and from U.S. provisional application No. 60/234,500, filed Sep. 22, 2000.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60185617 |
Feb 2000 |
US |
|
60234500 |
Sep 2000 |
US |